Elanco Animal Health Incorporated
Every calculator, already run for ELAN
Open the full toolkit →You have the numbers on ELAN. Get the argument.
A written report on which of these readings actually decide the outcome for Elanco Animal Health Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering ELANAnalyst Price Target Disagreement for Elanco Animal Health Incorporated
Wall Street's bull case implies +50% from the current price; the bear case implies +14%. A 35% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutic…
ELAN — frequently asked
Is ELAN a buy right now?
Wall Street's consensus rating on Elanco Animal Health Incorporated is Strong Buy across 17 analysts, with a mean price target of $31.21 (+37% vs. the current $22.73). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ELAN overvalued?
ELAN trades at — trailing earnings, against a DCF fair value of $28 per share. The current price implies 3% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ELAN's next earnings date?
Elanco Animal Health Incorporated is next scheduled to report earnings around Nov 5, 2026. A full ELAN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Elanco Animal Health Incorporated?
Analysts covering Elanco Animal Health Incorporated (ELAN) range from a bear-case target of $26.00 to a bull-case high of $34.00, with a mean consensus target of $31.21 across 14 analysts. The spread of $8.00 (35% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Elanco Animal Health Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Elanco Animal Health Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ELAN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Elanco Animal Health Incorporated, in minutes. 3 free reports included with every account — no credit card required.